The All-Russian Scientific and Practical Conference “Stomach 2019. Metabolic organization of the functions of the stomach” took place at the beginning of February 2019.
A symposium "New directions and strategies of gastroenterological science and practice development” was held within the conference, with the support of Valenta Pharm. The symposium wasdedicated to the most pressing issues of the treatment of functional diseases of the gastrointestinal tract. The symposium was held under the leadership of the chief gastroenterologist of the Ministry of Health of Russia, academician of the RAS Vladimir Trofimovich Ivashkin. During the event the experts’ attention was specifically drawn to lectures of Vladimir Ilyich Simanenkov, Olga Andreyevna Storonova and Olga Alexeyevna Gromova. The lectures covered the issues of choosing an effective therapy for patients with the presence of several functional diseases of the gastrointestinal tract (so-called overlap syndrome).
In his report, Dr. med., Professor, head of the department of therapy and clinical pharmacology of the North-Western State Medical University named after I.I. Mechnikov, President of the St. Petersburg Association of Therapists, Chairman of the North-Western Branch of the Regional Gastroentorological Association, Simanenkov Vladimir Ilyich introduced the possibilities of modern therapy in the treatment of functional disorders of the gastrointestinal tract, including the key ones – the functional dyspepsia and irritable bowel syndrome. The expert focused the participants’ attention on the overlap syndrome, the main factors of which are genetic preconditions, psychological comorbidity, visceral hypersensitivity, and a general malfunctioning of gastric motility. Important aspects of drug therapy, such as compliance and polypharmacy, were not neglected. “It is crucial to understand, that as soon as we prescribe 5 different drugs to a patient, we increase side effects. To avoid this, it is necessary to use drugs that have a complex effect on the stomach and intestines simultaneously. Trimebutine (Trimedat®) is one of such complex drugs, which, with hypermotorics, reduces gastric motility, and, with hypomotorics, increases it. In practice, trimebutine (Trimedat®) acts as a good antispasmodic and has a local anesthetic effect that exceeds lidocaine’s. Under the influence of trimebutine (Trimedat®), the generation of a nociceptive signal is suppressed, i.e. there is no adequate signal for spasm, which comes from the spinal cord to the central nervous system – hence the visceral sensitivity, motility and migrating motor complex change. During trimebutine therapy, patients receive quick relief: the stomach stops hurting, the bowel movement normalizes, flatulence disappears”.
During her presentation within the lecture “Features of diagnosis and pharmacotherapy in patients with biliary reflux”, Dr. med., Prof. of the department of pharmacology, academic adviser at the Institute of Pharmacoinformatics of the Federal Research Center "Informatics and Management" of RAS, Olga Alexeyevna Gromova pointed out to the new-generation antacid Antareit®, containing the unique combination of magaldrate and simethicone1. The drug has a combination of effects: antacid, enveloping, adsorbing, carminative, cytoprotective and reparative, as well as in contrast with the old-generation drugs, containing a high concentration of mixtures of aluminum and magnesium, Antareit® has almost instant effect and does not form chronic alumotoxicosis2. “Studies by European pharmacologists have shown that magaldrate does not cause intoxication, dissolves well and begins to act immediately, quickly creating an even enveloping layer capable of keeping the proper PH balance of the gastric mucous up to 3 hours. In addition, the molecule structure allows to quickly restore the structure of the mucous tissue of the stomach, also accelerating the healing of erosions on the mucous tissue of the stomach and duodenum, thanks to good speed of cell division and migration, provided by magaldrate. Studies show that the combination of magaldrate and simethicone (which are parts of Antareit®) resembles a relay race, where the magaldrate works optimally in stomach – relieves heartburn, pain and a feeling of heaviness, and simethicone effectively eliminates gas formation problems in the intestines,” the expert noted.
A question and answer session was organized at the end of the symposium; participants discussed and exchanged practical experience and were able to ask interesting questions.
The scientific program of the conference was accredited by the Coordination Council for the Development of Continuing Medical and Pharmaceutical Education (CME) of the Ministry of Health of Russia and provided educational loans as a part of the development of the basic principles of CME in the specialty: “Gastroenterology” More than 350 specialists from different Russian cities partook in the event.
- 1 Instruction for medical use of Antareit®.
- 2 Gromova O. A., Torshin I. Yu., Maksimov V. A. The characteristics of molecular-biological mechanisms of the antacid Antareit®: the multiplicity of therapeutic effects. Consilium Medicum. 2018; 20 (8). 106-110.